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Abstract
We describe three unrelated patients presenting with a spinal cord syndrome
and neuroimaging features consistent with multiple sclerosis (MS). All harbored
a pathogenic OPA1 mutation. Although the neurological phenotype resembled
neuromyelitis optica (NMO), anti-aquaporin 4 antibodies were not detected
and the disorder followed a slow progressive course. The coincidental occur-
rence of OPA1 mutations and an MS-like disorder is likely to have modulated
the phenotypic manifestations of both disorders, but unlike the previously
reported association of Leber hereditary optic neuropathy and MS (Harding
disease), the optic neuropathy in patients with OPA1 mutations and an MS-like
disorder can be mild with a good visual prognosis.
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Introduction
Mutations in OPA1 were first described in pedigrees with
autosomal-dominant optic atrophy (DOA), which is the
most common form of inherited optic nerve blindness in
the population.1,2 The visual loss in DOA develops in
early childhood and it has a relatively indolent course
with 10–20% of OPA1 mutation carriers remaining visu-
ally asymptomatic.3 Nonpenetrance is also well described,
which contributes to the lack of a clear-cut family history
in some affected probands.
OPA1 encodes for an inner mitochondrial membrane
protein that regulates a host of important functions,
including the balance between mitochondrial fusion and
fission, the stability of the mitochondrial respiratory chain
complexes, and the controlled release of proapoptotic
cytochrome c molecules sequestered within the mitochon-
drial cristae.4 DOA is therefore a mitochondrially deter-
mined optic neuropathy characterized by the preferential
loss of retinal ganglion cells within the inner retina, simi-
lar to Leber hereditary optic neuropathy (LHON).
In 1992, Anita Harding and colleagues described eight
female patients with the m.11778A>G mitochondrial
DNA (mtDNA) mutation who developed features of both
LHON and multiple sclerosis (MS).5 Subsequent reports
of MS occurring in association with all three primary
LHON mutations (m.3460A>G, m.11778A>G, and
m.14484T>C), raised the distinct possibility of a mecha-
nistic link between these two disorders,6–9 supported by
mounting evidence of mitochondrial dysfunction in both
acute and chronic MS lesions.10–12 Unlike classical
demyelinating optic neuritis, visual loss in LHON-MS
cases (also known as Harding disease) is frequently bilat-
eral at onset and the prognosis is poor with over half of
all patients being registered legally blind.13 However,
unlike the well-recognized link between LHON mtDNA
mutations and demyelination, the link between OPA1
mutations and MS is not well established. To date, an
MS-like illness has only been described in one patient
with an OPA1 mutation,14 although another patient had
coincidental MRI findings consistent with MS,15 and sev-
eral case series have described abnormal white matter
high signal changes in OPA1 mutation carriers.16–18 In
this report, we describe three additional unrelated white
Caucasian patients who presented to our tertiary neuro-
ophthalmological center with a clinically definite spinal
cord MS phenotype, and who were eventually found to
harbor pathogenic OPA1 mutations.
Subjects
Patient A
A 60-year-old woman presented with a 4-year history of
worsening gait and sensory disturbance that was accom-
panied by urinary urgency and nocturia. She had noticed
a slow deterioration in her vision from the age of
50 years, but she was still able to drive. Her mother was
registered blind in her later years and she also suffered
from Parkinson disease with dementia. The patient had
two unaffected sisters. On examination, she had a spastic
gait. Power in the lower limbs was normal, but there was
increased tone and sustained ankle clonus. Reflexes were
brisk and plantar responses were flexor. The patient had
a mild reduction in visual acuity and dyschromatopsia,
but there was no detectable visual field defect and pupil-
lary light reflexes were preserved (Table 1). Optic disc
pallor was noted on dilated fundus examination (Fig. 1).
MRI of the brain and spinal cord revealed multiple foci
of high T2 signal that were in keeping with demyelina-
tion (Fig. 2A). Oligoclonal bands were detected in the
patient’s cerebrospinal fluid (CSF). Routine hematologi-
cal, biochemical, and immunological blood tests were
normal, including folate and vitamin B12. Anti-aquaporin
Table 1. Clinical and molecular characteristics of the three patients with OPA1 mutations and an MS-like disorder.
Subject Age Sex OPA1 mutation
BCVA (Snellen)
Ishihara
plates (/15)
HumphreyTM fields
(MD)
Average
RNFL
thickness
(lm)1
RE LE RE LE RE LE RE LE
Patient A 60 F c.2356-1G>T 20/30 20/30 3 3 0.74 0.87 63 62
Patient B 56 M c.870+5G>A CF CF 0 0 N/A2 N/A2 64 65
Patient C 39 F c.870+5G>A 20/60 20/60 1 1 1.22 3.14 65 64
1Average peripapillary retinal nerve fiber layer thickness was measured using the high-resolution spectral-domain CirrusTM platform (Carl Zeiss
Meditec, Dublin, CA).
2Patient B was unable to perform HumphreyTM visual field perimetry. Goldmann fields showed bilateral dense central scotomas.
BCVA, best-corrected visual acuity; CF, counting fingers; LE, left eye; MD, mean deviation (dB); RE, right eye; RNFL, retinal nerve fiber layer.
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Figure 1. Optic discs appearance and optical coherence tomography (OCT) findings for Patient A. (A) Bilateral optic atrophy (RE, right eye; LE,
left eye); (B) OCT measurements were obtained with the high-resolution spectral-domain CirrusTM platform (Carl Zeiss Meditec, Dublin, CA). The
average peripapillary retinal nerve fiber layer thickness (RNFL) was 63 lm in the right eye (OD) and 62 lm in the left eye (OS). The analysis
software automatically selects the appropriate normative range for the patient and the peripapillary RNFL measurements (dark traces) are
represented within color-coded distribution centiles (bottom panel): (1) red < 1%, (2) yellow 1–5%, and (3) green 5–95%.
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4 antibodies were not present in the patient’s serum.
Genetic testing for the three primary mtDNA LHON
mutations was negative. The family history and atypical
presentation led us to request OPA1 genetic screening,
which identified a novel heterozygous splice site muta-
tion, c.2356-1G>T. No clinical improvement was
observed after an empirical 5-day course of intravenous
methylprednisolone. Although the patient’s vision has
remained stable, her spastic paraparesis has progressed
rapidly over the subsequent 3 years of follow-up (EDSS
6.0).
Patient B
A 56-year-old man was referred with an 8-year history of
progressive walking difficulties with stiffness and weakness
in his lower limbs, increasing balance difficulties and
paraesthesiae in both hands. His visual difficulties became
apparent at the age of 7 years and he has been registered
legally blind (Table 1). Both optic discs were globally pale
and optical coherence tomography (OCT) imaging
showed significant thinning of the retinal nerve fiber layer
(Fig. S1). The patient had marked asymmetric spastic
paraparesis, with the left lower limb being more severely
affected than the right. Reflexes were exaggerated at the
knees and hypoactive at the ankles. He had reduced sen-
sation to pinprick in a glove and stocking distribution,
and vibration sense was absent distally in all four limbs.
Neuroimaging was highly suggestive of inflammatory
demyelination (Fig. S2B). The patient did not have a
lumbar puncture. A comprehensive blood panel was nor-
mal and anti-aquaporin 4 antibodies were not detected.
OPA1 genetic testing revealed a previously
reported pathogenic heterozygous splice site mutation,
c.870+5G>A. No clinical response was obtained after a
three-day course of high-dose intravenous methylpred-
nisolone. His EDSS changed quickly between 2012 and
2015 to 6.0. Interestingly, we subsequently heard that the
Figure 2. Brain and spinal cord MRI abnormalities in three patients with a multiple sclerosis-like disorder and OPA1 mutations. Multiple foci of T2
hyperintensity were observed in the periventricular and pericallosal white matter regions. Discreet areas of signal abnormalities were also present
in the cervical spinal cord, none of which were longitudinally extensive. Taken together, these neuroradiological findings met the MRI diagnostic
criteria for multiple sclerosis. Panel A is patient A, panel B is patient B, and panel C is patient C. Upper panel A = axial T2-weighted imaging,
lower panel A = sagittal T2-weighted imaging. Upper panel B = axial T1-weighted imaging, lower panel B = sagittal T2-weighted imaging. Upper
panel C = axial T2-weighted imaging, lower panel C = sagittal T2-weighted imaging.
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patient’s son had been diagnosed with relapsing-remitting
MS and he was receiving disease-modifying therapy. The
son did not harbor the OPA1 mutation that was identi-
fied in his father.
Patient C
A 39-year-old woman first presented in 2002 with paraes-
thesiae affecting both upper limbs, which lasted for
4 weeks before recovering fully. She represented in 2012
with bilateral numbness and paraesthesiae progressing
from her feet to her knees over 1 week. There was accom-
panying tingling of the hands and positive L’Hermitte’s
phenomenon. She complained of gradually worsening
vision from her early teenage years with no episodes of
acute deterioration (Table 1). On dilated fundus examina-
tion, bilateral optic disc pallor was noted (Fig. S2). Her
mother and a maternal uncle were also known to have
bilateral optic atrophy, but with no overt neurological def-
icits. The rest of the patient’s neurological examination
was normal except for reduced vibration sense to the knee
(EDSS 2.5). MRI of the brain and spinal cord revealed dis-
seminated white matter lesions consistent with demyelina-
tion (Fig. 2C). CSF was not examined. The patient tested
negative for anti-aquaporin 4 antibodies and the three pri-
mary mtDNA LHON mutations (m.3460A>G,
m.11778A>G, and m.14484T>C). Given the family history,
OPA1 genetic testing was requested and a heterozygous
splice site mutation, c.870+5G>A, was detected.
Discussion
The patients described in our case series fulfilled the
revised McDonald criteria for a diagnosis of MS, with
patients A and B having a primary progressive course,
and patient C having a relapsing-remitting course.19 All
three patients harbored OPA1 splice site mutations: the
previously described c.870+5G>A variant, and a novel
c.2356-1G>T variant that affects the canonical splice
acceptor site. The OPA1 c.870+5G>A mutation causes
early-onset visual loss with a mean age of onset of
10 years old and visual acuities ranging from 20/30 to
counting fingers.3 Two patients with this specific splice
site mutation have also been reported where the optic
atrophy was complicated by myopathy and peripheral
neuropathy, but with no evidence of demyelination.15 MS
affects an estimated 2 in 1000 people in the United
Kingdom,20 and the prevalence of OPA1-positive DOA is
2.9 per 100,000 in the North of England.21 Approxi-
mately, 1 in 18 million of the population or 3–4 people
in the UK, will therefore be expected to have both an
MS-like disorder and carry OPA1 mutations purely by
chance. This would explain a case we previously described
of a 58-year-old woman with an OPA1 splice site muta-
tion within intron 25 (c.2613+1G>A) who was unexpect-
edly found to have MRI findings consistent with
demyelination, in the absence of any clear neurological
deficits.15
Although the three patients we describe here are likely
to be a coincidental occurrence, their clinical presenta-
tions are not entirely classical for either MS or DOA. As
OPA1 mutation carriers, they had an underlying predis-
position to develop an optic neuropathy which progressed
slowly over time, and all three patients developed a spinal
cord syndrome.22 Unlike Patient B and Patient C who
became aware of progressive visual deterioration in child-
hood, Patient A had an unusual late presentation in her
early fifties with only a mild reduction in central vision
(20/30 in both eyes). Although the sensory symptoms
resolved in Patient C, suggestive of an acute inflammatory
attack, the spinal cord syndromes were relentlessly pro-
gressive in the remaining two patients, with a relatively
rapid deterioration compared to typical primary progres-
sive multiple sclerosis. This would usually imply ongoing
lingering inflammatory disease, but there was no response
to high-dose intravenous methylprednisolone in any of
the patients described here. The most likely explanation is
an accelerated neurodegenerative mechanism probably
mediated by mitochondrial dysfunction. Bilateral visual
failure with a spinal cord syndrome suggests NMO, but
our patients were aquaporin-4 antibody negative, making
this diagnosis unlikely. Anti-MOG antibody testing was,
however, not performed.
The MS-DOA overlap syndrome that we describe here
seems distinct from the well-established association between
LHON and MS.5–9 With over 60 cases described to date,
patients with LHON-MS typically develop bilateral visual
failure that is severe, irreversible, and punctuated by recur-
rent episodes of acute or subacute deterioration.13 Although
a spinal cord presentation has been described, this is an
infrequent occurrence. The majority of patients with
LHON-MS present with sequential visual loss and the pre-
dominant neurological phenotype follows a relapsing-
remitting course.13 These contrasting observations are
intriguing because both LHON and DOA are mitochondrial
optic neuropathies that primarily target the retinal ganglion
cells, resulting in a monosymptomatic ocular disease.23
However, the spectrum of OPA1 disease is not limited to
the optic nerve and about 20% of mutation carriers can
develop additional features, in particular, chronic progres-
sive external ophthalmoplegia, ataxia, and peripheral neu-
ropathy.15 In comparison, these classical multisystemic
features of mitochondrial disease are rare in LHON.23 Dif-
ferent disease mechanisms are therefore likely to be involved
in the development of the more severe neurological “plus”
features in OPA1 and LHON mtDNA mutation carriers.
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The characteristic vulnerability of the spinal cord seen in
the three patients in our case series further highlights the
complexity, and the limits of our knowledge, in fully under-
standing the pathological pathways that modulate mito-
chondrial neurodegeneration in MS. Clinicians should
consider the possibility of an OPA1-related MS-like disor-
der in a patient presenting with progressive visual failure
and neuroimaging features indicative of a more dissemi-
nated inflammatory process. This could lead to the identifi-
cation of a pathogenic OPA1 mutation, which will have
important implications for the rest of the family and require
appropriate genetic counseling. It would also allow the clin-
ician to give a more guarded visual prognosis than would
normally be the case in a typical case of demyelinating optic
neuritis associated with MS.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. Optic discs appearance and OCT findings for
Patient B. (A) Bilateral optic atrophy (RE, right eye; LE,
left eye). (B) Optical coherence tomography (OCT) mea-
surements were obtained with the high-resolution spec-
tral-domain CirrusTM platform (Carl Zeiss Meditec,
Dublin, CA). The average retinal nerve fiber layer thick-
ness was 64 lm in the right eye (OD) and 65 lm in the
left eye (OS).
Figure S2. Optic discs appearance and OCT findings for
Patient C. (A) Bilateral optic atrophy (RE, right eye; LE,
left eye). (B) Optical coherence tomography (OCT) mea-
surements were obtained with the high-resolution spec-
tral-domain CirrusTM platform (Carl Zeiss Meditec,
Dublin, CA). The average retinal nerve fiber layer thick-
ness was 65 lm in the right eye (OD) and 64lm in the
left eye (OS).
ª 2016 American Counseling Association. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of
American Neurological Association. 729
P. Yu-Wai-Man et al. OPA1 Mutations and Demyelination
